Anaphylaxis caused by in-season switchover of sublingual immunotherapy formulation

Pediatric Allergy and Immunology

Volumn 25, Issue 7, 2014, Pages 714-715

  Hsiao, Kuang Chih ^a,b,c   Smart, Joanne ^a,c  

^a EPWORTH HEALTHCARE   (Australia)

^b MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; CETIRIZINE; CORTICOSTEROID; IPRATROPIUM BROMIDE; POLLEN EXTRACT; PREDNISOLONE; SALBUTAMOL; ALLERGEN; PLANT ANTIGEN; PLANT EXTRACT; SWEET VERNAL, ORCHARD, PERENNIAL RYE, TIMOTHY AND KENTUCKY BLUE GRASS MIXED POLLENS ALLERGEN EXTRACT;

ALLERGIC RHINITIS; ANAPHYLAXIS; CASE REPORT; CHILD; CYNODON DACTYLON; FEMALE; GRASS POLLEN; HAY FEVER; HUMAN; INFORMED CONSENT; LETTER; LOLIUM MULTIFLORUM; MEDICAL HISTORY; OBSERVATIONAL STUDY; OFF LABEL DRUG USE; PASPALUM NOTATUM; PERSONAL EXPERIENCE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; STRIDOR; SUBLINGUAL IMMUNOTHERAPY; WHEEZING; COMPLICATION; DESENSITIZATION; DRUG SUBSTITUTION; IMMUNOLOGY; POLLEN; PROCEDURES; RHINITIS, ALLERGIC, SEASONAL; SEASON; SUBLINGUAL DRUG ADMINISTRATION; TREATMENT WITHDRAWAL;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; ANAPHYLAXIS; ANTIGENS, PLANT; CHILD; DESENSITIZATION, IMMUNOLOGIC; DRUG SUBSTITUTION; EPINEPHRINE; FEMALE; HUMANS; OFF-LABEL USE; PLANT EXTRACTS; POLLEN; RHINITIS, ALLERGIC, SEASONAL; SEASONS; WITHHOLDING TREATMENT;

EID: 84922218352     PISSN: 09056157     EISSN: 13993038     Source Type: Journal    
DOI: 10.1111/pai.12268     Document Type: Letter

References (10)

1. Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009: 123: 160-6.e3.
2. Malling H J, Montagut A, Melac M, et al. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. Clin Exp Allergy 2009: 39: 387-93.
3. Halken S, Agertoft L, Seidenberg J, et al. Five-grass pollen 300IR SLIT tablets: efficacy and safety in children and adolescents. Pediatr Allergy Immunol 2010: 21: 970-6.
4. Caminati M, Dama A, Schiappoli M, Senna G. Balancing efficacy against safety in sublingual immunotherapy with inhalant allergens: what is the best approach? Expert Rev Clin Immunol 2013: 9: 937-47.
5. ASCIA. Australasian Society of Clinical Immunology and Allergy: Guideline for adrenaline autoinjector prescription. 2013. URL: http://www.allergy.org.au/images/stories/anaphylaxis/2014/ASCIA_Guidelines_for_AAI_prescription_Dec_2013.pdf.
6. De Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy 2009: 64: 963-4.
7. Eifan A O, Keles S, Bahceciler N N, Barlan I B. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy 2007: 62: 567-8.
8. Reich K, Gessner C, Kroker A, et al. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis. Clin Ther 2011: 33: 828-40.
9. Schwab J A, Wolf H, Schnitker J, Wustenberg E. Safety and tolerability of an intra-seasonal initiation of the SQ-standardised grass allergy immunotherapy tablet: a non-interventional observational study investigating the feasibility during routine administration. Clin Drug Investig 2013: 33: 719-26.
10. Costa J, Carrapatoso I, Oliveira M B, Mafra I. Walnut allergens: molecular characterization, detection and clinical relevance. Clin Exp Allergy 2014: 44: 319-41.